TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Diane Holder, a director at Evolent Health, Inc. (NYSE:EVH), recently purchased 2,735 shares of the company’s Class A common stock, joining other executives in accumulating shares. According to InvestingPro data, management has been actively buying back shares, suggesting internal confidence despite the stock’s 74% decline over the past year. The shares were acquired on March 6, 2025, at a price of $9.33 per share, totaling approximately $25,517. Following this transaction, Holder’s total direct ownership stands at 70,584 shares. This acquisition reflects Holder’s continued investment in the healthcare management services company. With analyst price targets ranging from $12 to $20 and current undervaluation signals, investors can access comprehensive valuation analysis and 10 additional exclusive insights through InvestingPro’s detailed research report.
In other recent news, Evolent Health reported fourth-quarter results that did not meet analyst expectations, with adjusted earnings per share of -$0.02 missing the consensus estimate of $0.07. Revenue for the quarter was $646.5 million, falling short of the projected $652.2 million, although it marked a 16.3% increase year-over-year. For the full year 2024, Evolent Health reported revenue of $2.55 billion, a 30.1% growth over 2023. However, the company’s guidance for 2025 disappointed investors, with projected full-year revenue between $2.06 billion and $2.11 billion, below the $2.42 billion expected by analysts.
Piper Sandler adjusted its price target for Evolent Health to $16 from $17, maintaining an Overweight rating, following the company’s earnings report. The firm acknowledged the results were at the lower end of guidance but still better than anticipated. Meanwhile, Citizens JMP raised its price target for the company to $13, reaffirming a Market Outperform rating, and expressed optimism about the company’s management and financial outlook. Evolent Health’s management has been recognized for effectively managing challenges, with significant contract retention and new agreements expected to improve financial performance in 2025. These developments highlight the company’s ongoing efforts to stabilize and grow its financial performance amid market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.